The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Stool Microbiome Signature Associated with Response to Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Cancer
Open accessAbstract
Neoadjuvant pembrolizumab has been shown to be a valid treatment for patients affected by muscle-invasive bladder cancer (MIBC), as demonstrated in the PURE-01 clinical trial (NCT02736266). Among the tumor-extrinsic factors influencing immunotherapy efficacy, extensive data highlighted that the microbiome is a central player in immune-mediated anticancer activity. This report aimed to investigate the composition and role of stool microbiome in patients enrolled in the PURE-01 clinical trial. An orthotopic animal model of bladder cancer (MB49-Luc) was used to support some of the findings from human data. An analysis of stool microbiome before pembrolizumab was conducted for 42 patients, of whom 23 showed a pathologic response. The information in the preclinical model of orthotopic bladder cancer treated with anti-PD-1 antibody or control isotype was validated. Linear discriminant analysis effect size and linear models were used to identify the bacterial taxa enriched in either responders or nonresponders. The identified taxa were also tested for their association with event-free survival (EFS). Survival at 31 d after tumor instillation was used as the study endpoint in the preclinical model. Responders and nonresponders emerged to differ in terms of enrichment for 16 bacterial taxa. Of these, the genus Sutterella was enriched in responders, while the species Ruminococcus bromii was enriched in nonresponders. The negative impact of R. bromii on anti-PD-1 antibody activity was also observed in the preclinical model. EFS and survival of the preclinical model showed a negative role of R. bromii. We found different stool bacterial taxa associated with the response or lack of response to neoadjuvant pembrolizumab. Moreover, we provided experimental data about the negative role of R. bromii on immunotherapy response. Further studies are needed to externally validate our findings and provide mechanistic insights about the host-pathogen interactions in MIBC. PATIENT SUMMARY: Using prepembrolizumab stool samples collected from patients enrolled in the PURE-01 clinical trials, we identified some bacterial taxa that were enriched in patients who either responded or did not respond to immunotherapy. Using an animal model of bladder cancer, we gathered further evidence of the negative impact of the Ruminococcus bromii on immunotherapy efficacy. Further studies are needed to confirm the current findings and test the utility of these bacteria as predictive markers of immunotherapy response.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Increased gut microbiome diversity is closely associated with improved responses to ICIs.
“Numerous studies have shown that increased gut microbiome diversity is closely associated with improved responses to ICIs25,123,137,138.”
From Microbiome meets immunotherapy: unlocking the hidden predictors of immune checkpoint inhibitors (2025) · cites this paper as [123]
Citations
Cites
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J. J., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aao3290 · Cited by 3,107
Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients
Baruch, E. N., Youngster, I., Ben-Betzalel, G., Ortenberg, R., Lahat, A., Katz, L., Adler, K., Dick-Necula, D., Raskin, S., Bloch, N., et al. (2021) · Science · doi:10.1126/science.abb5920 · Cited by 1,757
Treatment of muscle‐invasive and advanced bladder cancer in 2020
Patel, V. G., Oh, W. K., & Galsky, M. D. (2020) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21631 · Cited by 1,029
Powles, T. B., Kockx, M. M., Rodríguez‐Vida, A., Durán, I., Crabb, S. J., van der Heijden, M. S., Szabados, B. E., Pous, A. F., Gravis, G., Anido, U., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0628-7 · Cited by 598
Jin, Y., Dong, H., Xia, L., Yang, Y., Zhu, Y., Shen, Y., Zheng, H., Yao, C., Wang, Y., & Lu, S. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.04.007 · Cited by 573
Mucosal Prevalence and Interactions with the Epithelium Indicate Commensalism of Sutterella spp.
Hiippala, K., Kainulainen, V., Kalliomäki, M., Arkkila, P., & Satokari, R. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.01706 · Cited by 351
Vertically transmitted faecal IgA levels determine extra-chromosomal phenotypic variation
Moon, C., Baldridge, M. T., Wallace, M. A., Burnham, C.-A. D., Virgin, H. W., & Stappenbeck, T. S. (2015) · Nature · doi:10.1038/nature14139 · Cited by 268
Basile, G., Bandini, M., Gibb, E. A., Ross, J. S., Raggi, D., Marandino, L., de Pádua, T. C., Crupi, E., Colombo, R., Colecchia, M., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2158 · Cited by 119
Self-citationPederzoli, F., Ferrarese, R., Amato, V., Locatelli, I., Alchera, E., Lucianò, R., Nebuloni, M., Briganti, A., Andrea Gallina, A., Colombo, R., et al. (2020) · European Urology Oncology · doi:10.1016/j.euo.2020.04.002 · Cited by 99
Self-citationBandini, M., Gibb, E. A., Andrea Gallina, A., Raggi, D., Marandino, L., Bianchi, M., Ross, J. S., Colecchia, M., Gandaglia, G., Fossati, N., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.09.011 · Cited by 85
Self-citationPederzoli, F., Bandini, M., Raggi, D., Marandino, L., Basile, G., Alfano, M., Colombo, R., Salonia, A., Briganti, A., Andrea Gallina, A., et al. (2021) · European Urology · doi:10.1016/j.eururo.2021.05.018 · Cited by 57
Self-citationThe Gut and Urinary Microbiota: A Rising Biomarker in Genitourinary Malignancies
Pederzoli, F., Murdica, V., Salonia, A., & Alfano, M. (2022) · Springer eBooks · doi:10.1007/978-3-030-80546-3_19 · Cited by 2
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Microbiome meets immunotherapy: unlocking the hidden predictors of immune checkpoint inhibitors
Huang, L., Li, Y., Zhang, C., Jiang, A., Zhu, L., Mou, W., Li, K., Zhang, J., Cui, C., Cui, X., et al. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00819-2 · Cited by 28
“Numerous studies have shown that increased gut microbiome diversity is closely associated with improved responses to ICIs 25,123,137,138 .”
Microbiome Modulation for the Treatment of Solid Neoplasms
Barragán-Carrillo, R., Zengin, Z. B., & Pal, S. K. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-00374 · Cited by 28
Venegoni, C., Tortorella, S., Caliendo, A., Locatelli, I., Coste, A. D., Locatelli, E., Capancioni, F., Bua, E., Camorani, S., Salonia, A., et al. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202403314 · Cited by 17
Self-citationThe role of the urinary microbiome in genitourinary cancers
Lee, S., Sfanos, K. S., & Singla, N. (2025) · Nature Reviews Urology · doi:10.1038/s41585-025-01011-z · Cited by 13
Jia, K., Chen, Y., Dai, D., Xie, Y., Peng, H., Cao, Y., Zou, H., Qiu, C., Tan, Y., zhang, X., et al. (2026) · BMC Medicine · doi:10.1186/s12916-025-04575-0 · Cited by 12
Anticancer Potential of Prebiotics: Targeting Estrogen Receptors and PI3K/AKT/mTOR in Breast Cancer
Sabit, H., Abouelnour, S., Hassen, B. M., Magdy, S., Yasser, A., Wadan, A.-H. S., Abdel-Ghany, S. E., Radwan, F. F. Y., Alqosaibi, A. I., Hafiz, H., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13040990 · Cited by 12
Zheng, Q., Zhong, Y., Lian, H., Zhuang, J., Wang, L., Chen, J., Wang, H., Wang, H., Ye, X., Huang, Z., et al. (2025) · United European Gastroenterology Journal · doi:10.1002/ueg2.70064 · Cited by 8
The Microbiome and Genitourinary Cancers: A New Frontier
Winslow, T. B., Gupta, S., Vaddaraju, V., Guercio, B. J., & Sahasrabudhe, D. M. (2025) · Cancers · doi:10.3390/cancers17223606 · Cited by 7
Clinical Applications of the Gut Microbiome in Genitourinary Cancers
Nguyen, C. B., & Vaishampayan, U. N. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_100041 · Cited by 7
Liu, Z., Lei, J., Yang, R., Cheng, L., Du, Y., Zhang, Y., Wang, J., & Liu, Y. J. (2025) · Journal of Environmental Management · doi:10.1016/j.jenvman.2025.126648 · Cited by 6
Wu, B., Quan, C., He, Y., Matsika, J., Huang, J., Liu, B., & Chen, J. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2371543 · Cited by 6
Zheng, Z., Xie, D., Han, Y., Li, G., Wang, S., Zhang, X., Huang, T., Xu, W., & Wu, G. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1699308 · Cited by 5
The Role of the Microbiome in Cancer Therapies
Chalif, J., Goldstein, N. E. S., Mehra, Y., Spakowicz, D. J., & Chambers, L. (2025) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2024.12.005 · Cited by 5
Microbiome landscapes of the bladder, intestine, and vagina in bladder cancer: a systematic review
Surber, J., Semmler, M., Enderlin, D., Affentranger, A., Scherer, T. P., Sigg, S., Kaufmann, E., Gadient, J., Truscello, L., Scharl, M. M., et al. (2025) · Discover Oncology · doi:10.1007/s12672-025-02165-3 · Cited by 5
Reddy, N., Lau, K., Naman, J., Lu, K., McGillivary, E., Salmasi, A., Liss, M. A., & Stewart, T. F. (2026) · Oncoimmunology · doi:10.1080/2162402x.2025.2611458 · Cited by 2
Rosis, S. D., Monaco, G., Hu, J. K., Hett, E., Lappano, R., Marincola, F. M., Asadi, A., & Maggiolini, M. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06839-y · Cited by 4
DeepCRC: Precision Colorectal Cancer Diagnosis Using Deep Learning and Metagenomic Biomarkers
Wang, H., Li, Y., Feng, Y. X., Shen, K., Lu, C. F., & Xie, Z. (2024) · IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm62325.2024.10822422 · Cited by 3
Ronchi, F., Hinterbrandner, M., Rubino, V., Römmele, M., Chiorazzo, T., Mooser, C., Ganal-Vonarburg, S. C., McCoy, K. D., Bhatia, R., Macpherson, A. J., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116753 · Cited by 4
Yamaguchi, K., Sekido, K., Kobayashi, E., Ogura, K., Nishiyama, M., Konno, K., Tanaka, R., Hamana, H., Kishi, H., Sasaki, S., et al. (2026) · Journal of Natural Medicines · doi:10.1007/s11418-025-01999-z · Cited by 2
Orletskaia, V., & Olekhnovich, E. I. (2026) · Computational and Structural Biotechnology Journal · doi:10.34133/csbj.0065 · Cited by 4
Understanding the microbiome as a mediator of bladder cancer progression and therapeutic response
Golshani, M., Taylor, J. A., & Woolbright, B. L. (2024) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2024.07.004 · Cited by 2
Ma, Y., Zhou, Y., Xie, G., Chen, H., Huangfu, Y., Shen, L., Liu, Y., & Wang, P. (2025) · Discover Oncology · doi:10.1007/s12672-025-02338-0 · Cited by 1
Microbiome‐urothelium crosstalk in bladder cancer: From dysbiosis to clinical translation
Xu, H., Li, Z., Yang, L., Zheng, J., Li, W., Liao, R., Huang, W., Sun, B., Li, Z., Ma, C., et al. (2026) · iMetaOmics. · doi:10.1002/imo2.70081 · Cited by 1
Lorenzo, G. D., Maio, M. D., & Buonerba, C. (2026) · Oncology and Therapy · doi:10.1007/s40487-026-00417-y · Cited by 1
Luo, Z., Xu, D., Wang, Z., Wu, L., Ou, C., & Ou, Z. (2026) · Genes & Diseases · doi:10.1016/j.gendis.2026.102270 · Cited by 1
Gut microbiome’s effect on immunotherapy response
Masone, M. C. (2024) · Nature Reviews Urology · doi:10.1038/s41585-024-00854-2 · Cited by 1
Lucianò, R., Colecchia, M., Sanvito, F., Locatelli, I., Venegoni, C., Coste, A. D., Zani, D. D., Stranieri, A., Giudice, C., Rigillo, A., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1590073
Self-citationAdvances of mRNA vaccines in genitourinary cancers
Shen, Y.-M., Wan, F., Xu, H., Yu, L., Huang, S., Ye, D., & Dai, B. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189427
Distinguishing the significance of blood microbes in epithelial ovarian cancer
Mahoney, D. E., Chalise, P., Pei, D., Griffard-Smith, R., Home, T., Pathak, H. B., Umar, S., & Godwin, A. (2026) · Gut Microbes Reports · doi:10.1080/29933935.2026.2623562
Locatelli, I., Lorenzoni, M., Venegoni, C., Coste, A. D., Sorrentino, R., Jose, J., Cirillo, D. M., Weber, P., Manchala, A., Hosse, R. J., et al. (2026) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-026-03667-w
Self-citationPrognostic and predictive factors of immune checkpoint inhibitor therapy in urinary bladder cancer
Váradi, M., Magyar, B., Széles, Á. D., Korda, S., Németh, B., Simon, B. F., Reis, H., Oláh, C., Horváth, O. N., Dér, B., et al. (2026) · Pathology & Oncology Research · doi:10.3389/pore.2026.1612333
Mechanisms of microbiome-immune interactions in bladder cancer and targeted regulatory strategies
Wu, S., Fu, S., Shi, H.-J., Gong, Y.-C., Chen, P., Zhang, X.-Y., Jiang, E.-Y., & Wang, H.-F. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1920567
Biazzo, M., Soriani, M., Micallef, M. P., Zaky, E., & Podrini, C. (2026) · Microorganisms · doi:10.3390/microorganisms14102147
Metadata
- Authors
- Pederzoli, F., Riba, M., Venegoni, C., Marandino, L., Bandini, M., Alchera, E., Locatelli, I., Raggi, D., Giannatempo, P., Provero, P., Lazarevic, D., Moschini, M., Lucianò, R., Gallina, A., Briganti, A., Montorsi, F., Salonia, A., Necchi, A., & Alfano, M.
- Affiliations
- IRCCS Ospedale San Raffaele (IT)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Vita-Salute San Raffaele University (IT)
- Corresponding author
- Alfano, Massimo
- ORCID
- Venue
- European Urology
- Publisher
- Elsevier BV
- Published
- 2024-05
- Volume
- 85
- Issue
- 5
- Pages
- 417-421
- ISSN
- 0302-2838 (ISSN-L)
- OpenAlex
- W4390607935
- Cited by
- 33
- References
- 14
- Citations by year
- 2026: 12 · 2025: 16 · 2024: 5
- FWCI
- 5.65
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- European Urology (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion, cc-by-nc-nd)
- Funders
- AstraZeneca
- Merck
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Keywords
- pembrolizumab, neoadjuvant immunotherapy, muscle-invasive bladder cancer, immunotherapy response prediction, Ruminococcus bromii, Sutterella, anti-PD-1, event-free survival, predictive biomarkers
- MeSH terms
- Animals, Urinary Bladder Neoplasms, Humans, Muscles, Neoadjuvant Therapy, Ruminococcus, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
